A1874
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573175

CAS#: 2064292-12-0

Description: A1874 is a nutlin-based and BRD4-degrading PROTAC which induces BRD4 degradation in cells.


Chemical Structure

img
A1874
CAS# 2064292-12-0

Theoretical Analysis

MedKoo Cat#: 573175
Name: A1874
CAS#: 2064292-12-0
Chemical Formula: C58H62Cl3F2N9O7S
Exact Mass: 1171.3527
Molecular Weight: 1173.6
Elemental Analysis: C, 59.36; H, 5.33; Cl, 9.06; F, 3.24; N, 10.74; O, 9.54; S, 2.73

Price and Availability

Size Price Availability Quantity
5.0mg USD 210.0 Ready to ship
10.0mg USD 350.0 Ready to ship
25.0mg USD 550.0 Ready to ship
50.0mg USD 850.0 Ready to ship
100.0mg USD 1450.0 Ready to ship
200.0mg USD 2250.0 Ready to ship
Bulk inquiry

Synonym: A1874, A-1874; A 1874;

IUPAC/Chemical Name: (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-N-(4-((1-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)carbamoyl)-2-methoxyphenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamide

InChi Key: IPNTVOAQOGRLQB-JJMBTQCASA-N

InChi Code: InChI=1S/C58H62Cl3F2N9O7S/c1-32-33(2)80-56-48(32)51(35-11-14-37(59)15-12-35)67-44(53-71-70-34(3)72(53)56)29-47(73)65-19-21-77-23-25-79-26-24-78-22-20-66-54(74)36-13-18-43(45(27-36)76-7)68-55(75)52-49(39-9-8-10-41(61)50(39)63)58(31-64,46(69-52)30-57(4,5)6)40-17-16-38(60)28-42(40)62/h8-18,27-28,44,46,49,52,69H,19-26,29-30H2,1-7H3,(H,65,73)(H,66,74)(H,68,75)/t44-,46-,49-,52+,58-/m0/s1

SMILES Code: O=C([C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(C2=CC=C(Cl)C=C2F)[C@H]1C3=CC=CC(Cl)=C3F)NC4=CC=C(C(NCCOCCOCCOCCNC(C[C@H]5C6=NN=C(C)N6C7=C(C(C)=C(C)S7)C(C8=CC=C(Cl)C=C8)=N5)=O)=O)C=C4OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM (induce BRD4 degradation in cells).
In vitro activity: Suppression of c-Myc or induction of p21CIP1/WAF1 -- either one alone -- will inhibit cell proliferation. HCT116 cells incubated with JQ1 or idasanutlin for 48h showed clear dose-dependent loss of viability (Figure 3A). Treatment with JQ1 resulted in 25% loss of MTS signal compared to control cells; and idasanutlin treatment caused a 62% loss. However, treatment with A1874, which combines the activities of the two inhibitors, ultimately resulted in a 97% loss in HCT116 cell viability. That the effect of A1874 was greater than either idasanutlin or JQ1 alone, and even slightly more effective than a combined treatment (Supplementary Figure S1), demonstrates that combining both activities into a single PROTAC does not result in one activity diminishing the other. Reference: Cancer Res. 2019 Jan 1; 79(1): 251–262. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318015/
In vivo activity: By recording tumor growth curve, this demonstrated that A1874 oral administration (20 mg/kg, daily, 21 days) potently inhibited colon cancer xenograft growth in SCID mice (Fig. 5a). Calculating the estimated daily tumor growth, using the formula: (Tumor volume at D42—Tumor volume at D0)/42 (days), this study found that colon cancer xenograft growth was largely inhibited in A1874-treated mice (Fig. 5b). Tumors from the two groups were isolated and weighted individually at experimental Day-42 (D42). Xenograft tumors with A1874 administration were significantly lighter than those of vehicle control mice (Fig. 5c). Mouse body weights were not significantly different between A1874-treated and vehicle control mice (Fig. 5d), and no noticeable toxicity was observed in the mice. These results show that oral administration of A1874 is able to inhibit colon cancer xenograft growth in SCID mice. Reference: Cell Death Dis. 2020 Sep; 11(9): 805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519683/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 125.0 106.51
Ethanol 100.0 85.21

Preparing Stock Solutions

The following data is based on the product molecular weight 1173.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Qin AC, Jin H, Song Y, Gao Y, Chen YF, Zhou LN, Wang SS, Lu XS. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis. 2020 Sep 25;11(9):805. doi: 10.1038/s41419-020-03015-6. PMID: 32978368; PMCID: PMC7519683. 2. Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2019 Jan 1;79(1):251-262. doi: 10.1158/0008-5472.CAN-18-2918. Epub 2018 Nov 1. PMID: 30385614; PMCID: PMC6318015.
In vitro protocol: 1. Qin AC, Jin H, Song Y, Gao Y, Chen YF, Zhou LN, Wang SS, Lu XS. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis. 2020 Sep 25;11(9):805. doi: 10.1038/s41419-020-03015-6. PMID: 32978368; PMCID: PMC7519683. 2. Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2019 Jan 1;79(1):251-262. doi: 10.1158/0008-5472.CAN-18-2918. Epub 2018 Nov 1. PMID: 30385614; PMCID: PMC6318015.
In vivo protocol: 1. Qin AC, Jin H, Song Y, Gao Y, Chen YF, Zhou LN, Wang SS, Lu XS. The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells. Cell Death Dis. 2020 Sep 25;11(9):805. doi: 10.1038/s41419-020-03015-6. PMID: 32978368; PMCID: PMC7519683.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-recruiting PROTAC Offers Superior, Synergistic Anti-proliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2018 Nov 1. pii: canres.2918.2018. doi: 10.1158/0008-5472.CAN-18-2918. [Epub ahead of print] PubMed PMID: 30385614.

A1874

5.0mg / USD 210.0